<DOC>
	<DOCNO>NCT02264990</DOCNO>
	<brief_summary>This 2-arm , Phase 3 study evaluate safety efficacy veliparib plus carboplatin paclitaxel versus Investigator 's choice standard chemotherapy current former smoker receive first cytotoxic therapy metastatic advance non-squamous non-small cell lung cancer .</brief_summary>
	<brief_title>Study Comparing Veliparib Plus Carboplatin Paclitaxel Versus Investigator 's Choice Standard Chemotherapy Subjects Receiving First Cytotoxic Chemotherapy Metastatic Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current Former Smokers</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Subject must ≥ 18 year age . Life expectancy &gt; 12 week . Subject must cytologically histologically confirm advanced metastatic nonsquamous NSCLC current former smoker . Subject must NSCLC amenable surgical resection radiation curative intent time screen . Subject must least 1 unidimensional measurable NSCLC lesion CT scan define RECIST ( version 1.1 ) . Subject know hypersensitivity paclitaxel drug formulate polyethoxylated castor oil ( Cremophor ) . Subject know hypersensitivity platinum compound . Subject peripheral neuropathy ≥ grade 2 . Subject squamous NSCLC , untreated know EGFR mutation exon 19 deletion L858R mutation exon 21 , know ALK gene rearrangement . Subject receive prior cytotoxic chemotherapy chemoradiotherapy NSCLC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>cisplatin</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>Poly Adenosine diphosphate ( ADP ) -ribose Polymerase ( PARP )</keyword>
	<keyword>Non-squamous</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>carboplatin</keyword>
	<keyword>Metastatic</keyword>
	<keyword>veliparib</keyword>
</DOC>